18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma

被引:15
作者
Kahraman, Deniz [1 ]
Theurich, Sebastian [2 ]
Rothe, Achim [2 ]
Kuhnert, Georg [1 ]
Sasse, Stephanie [2 ]
Scheid, Christoph [2 ]
Dietlein, Markus [1 ]
Drzezga, Alexander [1 ]
von Bergwelt-Baildon, Michael [2 ]
Kobe, Carsten [1 ]
机构
[1] Univ Hosp Cologne, Dept Nucl Med, D-50937 Cologne, Germany
[2] Univ Hosp Cologne, Dept Internal Med 1, D-50937 Cologne, Germany
关键词
Hodgkin lymphoma; brentuximab vedotin; treatment response assessment; FDG-PET/CT; STEM-CELL TRANSPLANTATION; FDG-PET; INTERIM; CHEMOTHERAPY; CRITERIA; ABVD; STANDARD; PHASE-2; DISEASE; PREDICT;
D O I
10.3109/10428194.2013.819575
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Brentuximab vedotin has emerged as a possible treatment option in patients suffering from relapsed and refractory Hodgkin lymphoma (HL). We investigated the role of 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for monitoring treatment response to brentuximab vedotin in patients with relapsed and refractory HL. Twelve consecutive, heavily pretreated patients with relapsed and refractory HL treated with brentuximab vedotin were available for analysis. FDG-PET/CT studies were performed early during treatment after a median of 3 cycles (range, 2-5 cycles), and were analyzed visually using a 5-point scale (5PS) and quantitatively using the maximum standardized uptake value (SUVmax) and the three-dimensional (3D) isocontour at 50% of the maximum pixel value (SUV50) in the hottest single lesion. The median follow-up in our study cohort was 16 months (range, 5-30 months). The median progression-free survival (PFS) was 12.5 months and PFS at 12 months was 58%. Patients treated with brentuximab vedotin and negative interim FDG-PET/CT assessed by visual or quantitative analysis demonstrated a significantly prolonged PFS compared to patients with positive interim FDG-PET/CT. The 1-year PFS was 100% in patients with negative interim FDG-PET/CT assessed by visual analysis, whereas patients with positive interim FDG-PET/CT had a worse outcome with a 1-year PFS of 38% (p = 0.033). The 1-year PFS was 75% in patients with negative interim FDG-PET/CT assessed by quantitative analysis using the SUV50, whereas patients with positive interim FDG-PET/CT had a worse outcome with a 1-year PFS of 25% (p = 0.017) Interim FDG-PET/CT might be a suitable diagnostic approach to predict response to brentuximab vedotin in relapsed and refractory HL.
引用
收藏
页码:811 / 816
页数:6
相关论文
共 21 条
[1]  
Boellaard R, 2004, J NUCL MED, V45, P1519
[2]   Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments [J].
Boellaard, Ronald .
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 :93S-100S
[3]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[4]   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Hasenclever, D ;
Tesch, H ;
Herrmann, R ;
Dörken, B ;
Müller-Hermelink, H ;
Dühmke, E ;
Loeffler, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395
[5]   Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study [J].
Engert, Andreas ;
Diehl, Volker ;
Franklin, Jeremy ;
Lohri, Andreas ;
Doerken, Bernd ;
Ludwig, Wolf-Dieter ;
Koch, Peter ;
Haenel, Mathias ;
Pfreundschuh, Michael ;
Wilhelm, Martin ;
Truemper, Lorenz ;
Aulitzky, Walter-Erich ;
Bentz, Martin ;
Rummel, Mathias ;
Sezer, Orhan ;
Mueller-Hermelink, Hans-Konrad ;
Hasenclever, Dirk ;
Loeffler, Markus .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4548-4554
[6]   SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: Is there a benefit for PPV in early response assessment by FDG-PET? [J].
Furth, Christian ;
Meseck, Robert M. ;
Steffen, Ingo G. ;
Schoenberger, Stefan ;
Denecke, Timm ;
Henze, Guenter ;
Hautzel, Hubertus ;
Hofheinz, Frank ;
Grosser, Oliver ;
Hundsdoerfer, Patrick ;
Amthauer, Holger ;
Ruf, Juri .
PEDIATRIC BLOOD & CANCER, 2012, 59 (03) :475-480
[7]   Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma [J].
Kasamon, Yvette L. ;
Jacene, Heather A. ;
Gocke, Christopher D. ;
Swinnen, Lode J. ;
Gladstone, Douglas E. ;
Perkins, Brandy ;
Link, Brian K. ;
Popplewell, Leslie L. ;
Habermann, Thomas M. ;
Herman, Joseph M. ;
Matsui, William H. ;
Jones, Richard J. ;
Ambinder, Richard F. .
BLOOD, 2012, 119 (18) :4129-4132
[8]   Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? [J].
Kostakoglu, Lale ;
Schoeder, Heiko ;
Johnson, Jeffrey L. ;
Hall, Nathan C. ;
Schwartz, Lawrence H. ;
Straus, David J. ;
LaCasce, Ann S. ;
Jung, Sin-Ho ;
Bartlett, Nancy L. ;
Canellos, George P. ;
Cheson, Bruce D. .
LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2143-2150
[9]   Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria [J].
Le Roux, Pierre-Yves ;
Gastinne, Thomas ;
Le Gouill, Steven ;
Nowak, Emmanuel ;
Bodet-Milin, Caroline ;
Querellou, Soiene ;
Mahe, Beatrice ;
Dubruille, Viviane ;
Blin, Nicolas ;
Salaun, Pierre Yves ;
Bodere-Kraeber, Francoise .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (06) :1064-1071
[10]   Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone [J].
Markova, Jana ;
Kahraman, Deniz ;
Kobe, Carsten ;
Skopalova, Magdalena ;
Mocikova, Heidi ;
Klaskova, Katerina ;
Dedeckova, Katerina ;
Eich, Hans-Theodor ;
Boell, Boris ;
Dietlein, Markus ;
Kozak, Tomas .
LEUKEMIA & LYMPHOMA, 2012, 53 (01) :64-70